Two amazing health technology discoveries to help our well-being
Medical technology offers the scientific knowledge in the service of patients, to improve the treatments, cares and prevention of disease. The process of health technology assessment summarizes medical, social, economic and ethical data in order to ensure that the technology is used in a systematic, transparent and impartially way, and well hinged. In this respect, allows the development of safe and effective health policies oriented towards patients. Although its objectives are political in nature, must not lose contact with the strong research and scientific methods. Among the examples of medical technology are included: diagnostic and treatment methods, medical equipment, pharmaceuticals, rehabilitation and prevention methods, organizational and support systems within which health care is provided, etc.
Using similar materials that allow computer messages rapid transfer, the IBM researchers have developed a gel which kills germs. Although the company has supplied for a long time IT technology for the healthcare sector, its efforts to develop its own pharmaceutical product are much more recent, writes Financial Times. The IBM nano-medicine program through which was developed the new gel was initiated four years ago. "The techniques and tools we used to make semiconductor type applications may allow accurate modeling of problems with social impact," said Bob Allen, senior manager in the chemical and advanced materials research program of IBM.
The main purpose of the gel, developed in collaboration with the Institute of Bioengineering and Nanotechnology, is to replace the antibiotics. The overuse of antibiotics has led to an increased resistance and increased health insurance costs in the U.S., with 20 billion dollars per year. At the same time has increased the average time spent in hospital by 8 days. While the classic anti-bacterial passing through the membrane of the microbe in order to destabilize its internal mechanism, the new IBM gel breaks the membrane such as an egg shell, and then extracts the infectious material.
More than 170 million people are carriers of the hepatitis C which develops serious liver disease. "Our findings are useful to the producers of drugs with activity against HCV," said Hengli Tang, a specialist in molecular biology. How does it work? The technology of medical investigation is called CoFIM and works to identify the "cellular cofactors" and their mechanisms of action. "Cellular cofactors' are proteins of the host cells which have been damaged by viruses.
Cyclophilin A is an essential cellular cofactor for C hepatitis infection, and a favorite target for new anti-HCV action which have cyclosporine A in their composition. It was found that not only the HCV dependence of cyclophilin A cofactor and the susceptibility to medicines containing cyclosporine A but also the regulators at cellular level, which are some "tiny RNA libraries', collections of molecules that have the ability to suppress genes action. The CoFIM device induces the HCV virus mutation, in vitro, in the absence of normal replication received from a certain molecular cofactor. CoFIM tracks changes occurred following the administration of medicines based on cyclosporine A, which inhibits the key cofactor. The C hepatitis infection can lead to cirrhosis, a serious disease of the liver.
Author's Bio:
Kathryn is the author for Chrisalexcorp. She also writes for a website scratch.net where you can get play scratch cards.
- The IBM applies the computer technology to antibiotics
Using similar materials that allow computer messages rapid transfer, the IBM researchers have developed a gel which kills germs. Although the company has supplied for a long time IT technology for the healthcare sector, its efforts to develop its own pharmaceutical product are much more recent, writes Financial Times. The IBM nano-medicine program through which was developed the new gel was initiated four years ago. "The techniques and tools we used to make semiconductor type applications may allow accurate modeling of problems with social impact," said Bob Allen, senior manager in the chemical and advanced materials research program of IBM.
The main purpose of the gel, developed in collaboration with the Institute of Bioengineering and Nanotechnology, is to replace the antibiotics. The overuse of antibiotics has led to an increased resistance and increased health insurance costs in the U.S., with 20 billion dollars per year. At the same time has increased the average time spent in hospital by 8 days. While the classic anti-bacterial passing through the membrane of the microbe in order to destabilize its internal mechanism, the new IBM gel breaks the membrane such as an egg shell, and then extracts the infectious material.
- The C hepatitis, cornered by a new medical technology
More than 170 million people are carriers of the hepatitis C which develops serious liver disease. "Our findings are useful to the producers of drugs with activity against HCV," said Hengli Tang, a specialist in molecular biology. How does it work? The technology of medical investigation is called CoFIM and works to identify the "cellular cofactors" and their mechanisms of action. "Cellular cofactors' are proteins of the host cells which have been damaged by viruses.
Cyclophilin A is an essential cellular cofactor for C hepatitis infection, and a favorite target for new anti-HCV action which have cyclosporine A in their composition. It was found that not only the HCV dependence of cyclophilin A cofactor and the susceptibility to medicines containing cyclosporine A but also the regulators at cellular level, which are some "tiny RNA libraries', collections of molecules that have the ability to suppress genes action. The CoFIM device induces the HCV virus mutation, in vitro, in the absence of normal replication received from a certain molecular cofactor. CoFIM tracks changes occurred following the administration of medicines based on cyclosporine A, which inhibits the key cofactor. The C hepatitis infection can lead to cirrhosis, a serious disease of the liver.
Author's Bio:
Kathryn is the author for Chrisalexcorp. She also writes for a website scratch.net where you can get play scratch cards.
Comments
Post a Comment